Tag Archives: CD10

Organ Systems, Bone Marrow, Lymph Node, WHO Classification

Follicular Lymphoma

Follicular Lymphoma (FL) is a mature B-cell lymphoma, which recapitulates or resembles germinal center B-cells.  Most cases (~85%) harbor the characteristic t(14;18), which juxtaposes the BCL-2 gene on chromosome 18 with the IgH gene on chromosome 14 (and hence BCL-2 IHC protein expression).  Most patients (~80-85) will present with advanced disease (stage III/IV), and bone marrow involvement is found in ~40% of cases with characteristic paratrabecular aggregates (mantle cell lymphoma and lymphoplasmacytic lymphoma may also have paratrabecular lymphoid aggregates).  Most of the cases that lack the t(14;18) IgH/BCL-2 translocation (and are BCL-2 negative) are typically grade 3 FLs with a BCL-6 translocation (~10-15%).  BCL-6 translocations can be evaluated for by FISH analysis, but the finding is NOT specific for FL.
 
Over time 30-50% of cases transform to diffuse large B-cell lymphoma (DLBCL).  In a small subset of transformations, a second “hit” with a MYC translocation will occur resulting in a very aggressive high grade large B-cell lymphoma: the so-called “double hit” lymphoma. 
Morphology
FL usually has at least a component of nodularity (+/- diffuse areas).  There are two cell types that make up FL, centrocytes and centroblasts.  Centrocytes are small cleaved cells with folded irregular nuclei.  Centorblasts are large cells with more open chromatin, multiple nucleoli, and more cytoplasm compared to centrocytes.  
 
Sometimes FL can have patterns that resemble marginal zone lymphoma, and can even have plasmacytic differentiation.  Therefore, it is important that a panel of markers be used to identify (or exclude) evidence of germinal center differentiation.  Occasional cases can have Hodgkin-like cells.
Immunophenotype 
Marker
Comment
Negative
Positive
Positive
Positive
  • Grade 1 – ~90%
  • Grade 2 – ~70%
  • Grade 3 – ~60%
Positive (~90%), negative cases do not contain the t(14;18), which is more common in grade 3 cases
  • Grade 1 – >90% + for BCL-2
  • Grade 2 – >80% + for BCL-2
  • Grade 3 – 50-70% + BCL-2
Positive, (~88%)
CD35
Highlights the follicular dendritic meshwork associated with FL.
Usually negative, higher grade lesions may be positive
Variable, shows low expression in low-grade processes, in distinct contrast to the high proliferation index and polarity associated with reactive germinal centers.
Negative
 
  
FL is typically expresses CD19, CD20, CD10, Bcl-6, and BCL-2 (~90%).  CD5 is not expressed in FL.  
  • Normal reactive germinal centers do not express Bcl-2.  In 90% of cases of FL, bcl-2 is expressed, which serves as a diagnostic tissue marker in lymphoma sections.
  • CD23 expression by flow cytometry has been associated with lower grade FLs (e.g. grade 1 & 2) and better survival.
Grading
  • Grade 1 & 2:  <= 15 centroblasts/HPF (based on 0.159 mm² HPF)
  • Grade 3:  > 15 centroblasts/HPF (based on 0.159 mm² HPF)
    • 3A:  Centrocytes present in the background
    • 3B:  NO centrocytes present in the background (not associated with the IgH/BCL-2 rearrangement, and usually lacks expression of CD10 and BCL-2; often MUM-1+)
Grade 1 & 2 behave in a similar fashion as a low grade lymphoma.  Grade 3 FL behaves as an intermediate grade lymphoma.  Grading of FL with counting of large cells must take into consideration the field diameter of the microscope being used.  The counts above are based on a F.N. 18 (0.159 mm² @ 40X).  Most convention pathology scopes today are F.N. 22 (0.247 mm² @ 40X), and adjustments are necessary.
Pattern
  • Predominately follicular:  >75% follicular/nodular architecture
  • Follicular and diffuse:  25-75% Diffuse areas or follicular/nodular architecture
  • Preominately diffuse:  <25% follicular/nodular areas (diffuse areas of otherwise grade 3 FL, then that component should be described as a separate component of diffuse large B-cell lymphoma)
Special Subtypes 
  • Large B-Cell Lymphoma with IRF4 Rearrangement
  • Pediatric Follicular Lymphoma
    • Occurs in children and young adults with an excellent prognosis, marked male predilection
    • The morphology is high-grade (FL grade 3) appearing
      • BCL-2 negative, lacK t(14;18)
      • CD10 + (usually)
      • MUM-1 negative
    • Associated with TNFRSF14 deletions of mutations
    • Localized process, usually in the head and neck area
  • Duodenal Follicular Lymphoma
    • Localized lesion
    • Grade 1-2 pattern
    • CD10/BCL-2 +
    • t(14;18) present
    • Lacks follicular dendritic meshwork
    • Ki-67, low expression
    • Excellent prognosis
  • Predominately Diffuse Follicular Lymphoma with 1p36 deletion
    • Localized mass (often inguinal)
    • Diffuse pattern, grade 1/2 
    • Excellent prognosis
    • Immunophenotype:  CD20+, CD10+, BCL-2+, BCL-6+, CD23+ (subset of cases)
    • t(14;18) NOT present
    • 1p36 deletion (not specific)
    • Lacks Bcl-2 rearrangement
  • Primary Cutaneous Follicular Lymphoma 
  • In Situ Follicular Neoplasm (ISFN)
References
Robbins and Cotran Pathologic Basis of Disease.  V Kumar, et al. 9th Edition. Elsevier Saunders. 2015. pp. 594-595.
 
Fedoriw Y, Dogan A. The Expanding Spectrum of Follicular Lymphoma. Surg Pathol Clin. 2016;9: 29–40. doi:10.1016/j.path.2015.11.001
 
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127: 2375–2390. doi:10.1182/blood-2016-01-643569
 
Xerri L, Dirnhofer S, Quintanilla-Martinez L, Sander B, Chan JKC, Campo E, et al. The heterogeneity of follicular lymphomas: from early development to transformation. Virchows Arch. 2016;468: 127–139. doi:10.1007/s00428-015-1864-y
 
MD DY-PW, BacSc F. A case of t (14; 18)-negative follicular lymphoma with atypical immunophenotype: usefulness of immunoarchitecture of Ki67, CD79a and follicular dendritic cell …. … Malaysian journal of …. 2014.
 
Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21: 116–131. doi:10.1097/PAI.0b013e31825d550a
 
Cook JR. Nodal and leukemic small B-cell neoplasms. Mod Pathol. 2013;26 Suppl 1: S15–28. doi:10.1038/modpathol.2012.180
 
Olteanu H, Fenske TS, Harrington AM, Szabo A, He P, Kroft SH. CD23 Expression in Follicular Lymphoma: Clinicopathologic Correlations. Am J Clin Pathol. 2011;135: 46–53. doi:10.1309/AJCP27YWLIQRAJPW
 
Gradowski JF, Jaffe ES, Warnke RA, Pittaluga S, Surti U, Gole LA, et al. Follicular lymphomas with plasmacytic differentiation include two subtypes. Mod Pathol. 2010;23: 71–79. doi:10.1038/modpathol.2009.146
 
Katzenberger T, Kalla J, Leich E, Stöcklein H, Hartmann E, Barnickel S, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009;113: 1053–1061. doi:10.1182/blood-2008-07-168682
 
Bayerl MG, Bentley G, Bellan C, Leoncini L, Ehmann WC, Palutke M. Lacunar and reed-sternberg-like cells in follicular lymphomas are clonally related to the centrocytic and centroblastic cells as demonstrated by laser capture microdissection. Am J Clin Pathol. 2004;122: 858–864. doi:10.1309/PMR8-6PHK-K4J3-RUH3
Organ Systems, WHO Classification

Hans’ Algorithm

Diffuse Large B-Cell Lymphoma represents a heterogeneous group of non-Hodgkin B-cell lymphoma cases that share a common architectural pattern and large cell size.  Subcategorization have been attempted with varying success based on morphology, immunophenotype, and molecular characteristics.  Gene expression profiling (GEP) has demonstrated two important groups for both prognosis and treatment.  Alizadeh, et al showed significant survival differences in cases of DLBCL with either a germinal center B-cell-like pattern or an activated B-cell-like pattern.
 
Unfortunately, GEP is not available in routine clinical practice, and multiple surrogate immunohistochemistry (IHC) based algorithms have been developed as a surrogate to GEP.  The Hans’ algorithm (classifier) has been one of the most popular methods because it uses only three IHC markers (CD10, Bcl-6, & MUM-1) that are commonly available in most pathology laboratories.  The following figure highlights the algorithm for the Hans’ classifier as described in the original paper.  The Hans’ algorithm appears to match GEP in 75-80% of cases.
 
Hans Classifier - CD10, Bcl-6, MUM-1
Hans classifier to subtype DLBCL as to germinal center B-cell-like (GCB) or non-germinal center B-cell-like (non-GCB) which has prognostic significance.
Alternative Algorithm(s)
The University of Nebraska group that originally developed the Hans algorithm has developed a new IHC stain algorithm that reportedly classifies cases of DLBCL more accurately compared to the corresponding molecular subtypes (~80% concordance).  This algorithm uses GCET1, CD10, BCL-6, MUM-1, and FOXP1 with differing cutoff values for positive/negative. (WW Choi, et al)  New algorithms with IHC markers not commonly used in many laboratories has probably limited popularity compared to the Hans’ algorithm.  The 2016 WHO hematopathology revision requires that cases of DLBCL be characterized at GCB vs. non-GCB by some acceptable methodology (molecular or IHC).
References
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103: 275–282. doi:10.1182/blood-2003-05-1545
 
Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med. 2006;130: 1819–1824.
 
Chang C-C, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28: 464–470.
 
Choi WWL, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15: 5494–5502. doi:10.1158/1078-0432.CCR-09-0113
 
Alizadeh AA, Elsen MB, Davis RE, Ma C. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000.
 
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127: 2375–2390. doi:10.1182/blood-2016-01-643569 
CD Markers, Antibody List

CD10

Hematopathology
CD10 (a.k.a. CALLA, common acute lymphoblastic leukemia antigen) is a useful marker for cells of germinal center cell origin and is expressed during the lymphoblastic phase of development.  Therefore, this marker is diagnostically helpful in several areas in hematopathology:  acute lymphoblastic leukemia (ALL), follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma.
 
ALL will often show expression of CD10.  In fact, CD10 co-expression with TdT is characteristic of ALL (additional expression of T- or B-cell markers will help further classify).
 
CD10 is  a marker of follicle center cell origin, which is characteristic of certain lymphomas including: follicular lymphoma, Burkitt lymphoma, and a subset of DLBCLs.
 
CD10 can be used as part of a prognostic panel (CD10, bcl-6, and MUM-1) in DLBCL to help separate cases into germinal center and non-germinal center subtypes.  The Hans’ (classifier) algorithm method is the most popular, probably due to the simplicity of the algorithm and utilization of IHC markers already present in most laboratories.
Non-Hematopathology
CD10 is a useful marker in non-lymphoid malignancies:  renal cell carcinoma and hepatocellular carcinoma.  CD10 will have a “bile canaliculi” pattern in HCC.  CD10 will also stain endometrial stromal sarcoma, and the “brush boarder” in GI tumors.
Pitfalls
CD10 can appear to have a lot of “non-specific” staining because of staining of dendritic stomal cells.  This can cause a pattern similar to reticular fibers, and many describe this as a “reticular pattern,” but the staining does not directly correlate with reticulin staining.  Caution should be exercised in using this stain in isolation given its lack of specificity (see below).
CD10 Expression in tumors often studied by CD10 IHC staining
Other tumors/tissues with CD10 expression (20-100% expression)
  • Hepatocellular Carcinoma
  • Breast myoepithelial cells and stromal fibroblasts
  • Cutaneous adnexal neoplasms
  • Mesothelioma
  • Epithelioid hemangioendotheliomas
  • Ovarian carcinoma
  • Urothelial carcinoma
  • Prostatic adenocarcinoma
  • Colon adenocarcinoma
  • Melanoma
  • Spindle cell carcinoma 
  • Lung carcinomas
  • Pancreatic solid pseudo papillary carcinoma
Photomicrographs
CD10 - Germinal Center
CD10 – Germinal Center
CD10 - Metastatic Renal Cell Carcinoma
CD10 – Metastatic Renal Cell Carcinoma
References
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103: 275–282. doi:10.1182/blood-2003-05-1545
 
Tan, P.-H., Cheng, L., Rioux-Leclercq, N., Merino, M. J., Netto, G., Reuter, V. E., et al. (2013). Renal tumors: diagnostic and prognostic biomarkers. (Vol. 37, pp. 1518–1531). Presented at the The American journal of surgical pathology. doi:10.1097/PAS.0b013e318299f12e
 
Chang, C.-C., McClintock, S., Cleveland, R. P., Trzpuc, T., Vesole, D. H., Logan, B., et al. (2004). Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. The American Journal of Surgical Pathology, 28(4), 464–470.  
 
Tan P-H, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, et al. Renal tumors: diagnostic and prognostic biomarkers. 2013. pp. 1518–1531. doi:10.1097/PAS.0b013e318299f12e
 
Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2010;135: 92–109. Available: http://www.archivesofpathology.org/doi/pdf/10.1043/2010-0478-RAR.1
 
Dewar R, Fadare O, Gilmore H, Gown AM. Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med. 2011;135: 422–429. doi:10.1043/2010-0336-CP.1
 
Alizadeh AA, Elsen MB, Davis RE, Ma C. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000.
 
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127: 2375–2390. doi:10.1182/blood-2016-01-643569
 
Bone Marrow IHC.  Torlakovic, EE, et. al. American Society for Clinical Pathology Pathology Press © 2009.  pp. 38.